Curiosis, Inc.
KKRX:4941208,190.00
KRW
+240.00
(+3.02%)
Curiosis, Inc.
KRX:494120
(Korea Stock Exchange)
Recent
price
8,190.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.- Similar Companies
- Business
- Curiosis, Inc. is a South Korea-based life sciences technology company that develops, manufactures, and commercializes automated bio-imaging instruments, optical diagnostic equipment, and microfluidics-based cell analysis platforms for biomedical research and clinical diagnostics. The company operates within the laboratory instrumentation and life sciences tools sector, providing solutions optimized for cell biology, drug discovery, immunology, and regenerative medicine. Curiosis offers a systematic portfolio of laboratory systems and consumables, including automated live-cell imaging systems marketed under the Celloger brand, featuring the Celloger Mini, Celloger Mini Plus, Celloger Pro, and Celloger Stack, which provide real-time, time-lapse brightfield and dual-fluorescence microscopic observation inside standard incubators; automated cell counters and viability analyzers utilizing disposable microfluidic hemocytometers; precision-engineered microfluidic chips, counting chambers, and assay consumables for cellular analysis; and proprietary image acquisition and analysis software platforms supporting automated confluence assessment, fluorescent signal quantification, and kinetic cell tracking. The company targets academic research institutions, biotechnology and pharmaceutical enterprises, contract research organizations, and hospital laboratories throughout South Korea, North America, Europe, and the broader Asia-Pacific region. Founded in 2015 and headquartered in Seoul, South Korea, Curiosis, Inc. listed its shares on the Korea Exchange under the ticker 494120. In recent operational and strategic developments, the company completed its public listing on the KRX via a special purpose acquisition company merger, launched next-generation multi-position and multi-fluorescence live-cell imaging instruments, and expanded its international commercial infrastructure through strategic distribution partnerships across key European and North American life science markets.